Marco Gottardis
Direttore/Membro del Consiglio presso LIfT BioSciences Ltd.
Posizioni attive di Marco Gottardis
Società | Posizione | Inizio | Fine |
---|---|---|---|
LIfT BioSciences Ltd.
LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | Direttore/Membro del Consiglio | 21/12/2023 | - |
Storia della carriera di Marco Gottardis
Formazione di Marco Gottardis
University of Wisconsin | Doctorate Degree |
The Trustees of Columbia University in The City of New York | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 3 |
Regno Unito | 2 |
Posizioni
Director/Board Member | 1 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Settori
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
LIfT BioSciences Ltd.
LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | Commercial Services |
- Borsa valori
- Insiders
- Marco Gottardis
- Esperienza